Compras y ventas de directivos de Gilead Sciences (GILD)
Qué compran y venden los consejeros y directivos del S&P 500 en sus propias empresas, tal cual lo presentan en los Formularios 4 de la SEC (2 días hábiles de plazo): cada fila con su código oficial y sin filtrar nada.
Las compras en mercado abierto (código P) son la señal rara, en verde; las ventas (código S) son frecuentes y muchas van programadas (10b5-1). La tabla II (derivados) no se incluye: sus precios son de ejercicio, no de mercado. Guía: compras de directivos.
| Fecha | Ticker | Directivo | Cargo | Acciones | Precio | Importe | % posición | Tipo / documento |
|---|
Descargar estas transacciones en CSV Sin cuenta y sin registro. Los datos son públicos: salen de los Formularios 4 de la SEC.
Compras y ventas de directivos de Gilead Sciences, Inc. (GILD): ninguna compra y 51 ventas
137 transacciones de la tabla I del Formulario 4 declaradas ante la SEC por directivos de Gilead Sciences, Inc. entre el 2025-08-29 y el 2026-10-16 (histórico de 15 meses): 0 compras y 51 ventas en mercado abierto, y 86 transacciones con otros códigos del Formulario 4, desglosados uno a uno más abajo. La mayor operación en mercado abierto es una venta de $17,3M de O'Day Daniel Patrick el 2026-02-05.
Compras y ventas de directivos de Gilead Sciences en los últimos 12 meses
Entre el 21 oct 2025 y el 20 oct 2026, los directivos de Gilead Sciences declararon 45 ventas por $87,9M en mercado abierto, y ninguna compra.
Quien más vendió fue O'Day Daniel Patrick (Chairman & CEO): $52,4M en 14 ventas, de 7 vendedores distintos.
La mayor operación del período fue una venta de $17,3M el 5 feb 2026, de O'Day Daniel Patrick (Chairman & CEO), dentro de un plan 10b5-1. Formulario 4 en sec.gov (0001638643-26-000010).
De las 45 ventas, 44 (el 98%, $87,3M) llevan en el Formulario 4 la marca de plan 10b5-1, es decir, se programaron con meses de antelación; la otra no la lleva.
En los tres últimos meses hay 11 ventas, frente a 9 en los tres anteriores. La última venta es del 15 oct 2026.
Frente a su sector (Salud, 59 empresas con página de directivos en esta web), en las mismas fechas la mediana es de 9 ventas y 0 compras en mercado abierto. Gilead Sciences tiene más ventas que 56 de las otras 58, es la 10.ª de 59 por dinero neto vendido, y 19 de las 59 tienen al menos una compra.
Las 20 operaciones más importantes
Como GILD no tiene compras en mercado abierto, la tabla empieza por sus ventas, de mayor a menor importe. El histórico completo está en la herramienta de arriba, ya buscado.
Ver las 137 operaciones de GILD en el histórico completo →
| Operación | Declarada | Directivo | Cargo | Importe | Código | Documento |
|---|---|---|---|---|---|---|
| 2026-02-05 | 2026-02-06 | O'Day Daniel Patrick | Chairman & CEO | $17,3M | S — Venta en mercado abierto (programada 10b5-1)Nota del Formulario 4 (texto original de la SEC, en inglés)F1 The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on February 28, 2025. | SEC |
| 2026-01-23 | 2026-01-26 | O'Day Daniel Patrick | Chairman & CEO | $15,6M | S — Venta en mercado abierto (programada 10b5-1)Nota del Formulario 4 (texto original de la SEC, en inglés)F1 The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on February 28, 2025. | SEC |
| 2025-11-12 | 2025-11-13 | Telman Deborah H | EVP, Corporate Affairs & GC | $6,6M | S — Venta en mercado abierto (programada 10b5-1)3 notas del Formulario 4 (texto original de la SEC, en inglés)F1 The transactions reported in the Form 4 are made pursuant to a Rule 10b5-1 trading plan adopted on August 13, 2025. F2 Sales prices for the transactions reported here range from $121.87 to $122.83. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request. F3 Sales prices for the transactions reported here range from $122.88 to $122.92. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request. | SEC |
| 2026-02-17 | 2026-02-18 | Mercier Johanna | Chief Comm & Corp Aff Officer | $4,3M | S — Venta en mercado abierto (programada 10b5-1)3 notas del Formulario 4 (texto original de la SEC, en inglés)F1 The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on February 20, 2025. F2 Sale prices for the transactions reported range from $153.565 to $154.56 Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request. F3 Sale prices for the transactions reported range from $154.57 to $155.27 Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request. | SEC |
| 2026-08-17 | 2026-08-18 | Mercier Johanna | Chief Comm & Corp Aff Officer | $3,9M | S — Venta en mercado abierto (programada 10b5-1)3 notas del Formulario 4 (texto original de la SEC, en inglés)F1 The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on February 20, 2025. F2 Sale prices for the transactions reported range from $136.74 to $137.73. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request. F3 Sale prices for the transactions reported range from $137.75 to $138.36. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request. | SEC |
| 2026-05-15 | 2026-05-18 | Mercier Johanna | Chief Comm & Corp Aff Officer | $3,7M | S — Venta en mercado abierto (programada 10b5-1)5 notas del Formulario 4 (texto original de la SEC, en inglés)F1 The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on February 20, 2025. F2 Sale prices for the transactions reported range from $129.66 to $130.63. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request. F3 Sale prices for the transactions reported range from $130.67 to $131.505. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request. F4 Sale prices for the transactions reported range from $131.71 to $132.55. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request. F5 Sale prices for the transactions reported range from $132.74 to $132.78. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request. | SEC |
| 2025-11-17 | 2025-11-18 | Mercier Johanna | Chief Commercial Officer | $3,5M | S — Venta en mercado abierto (programada 10b5-1)3 notas del Formulario 4 (texto original de la SEC, en inglés)F1 The transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan adopted on February 20, 2025. F2 Sales prices for the transactions reported here range from $125.23 to $126.20. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request. F3 Sales prices for the transactions reported here range from $126.23 to $126.39. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request. | SEC |
| 2026-08-26 | 2026-08-27 | Welters Anthony | Consejero | $2,7M | S — Venta en mercado abierto (programada 10b5-1)5 notas del Formulario 4 (texto original de la SEC, en inglés)F1 The transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan adopted on May 27, 2026. F2 Sale prices for the transactions reported range from $147.58 to $148.5799. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request. F3 Sale prices for the transactions reported range from $148.58 to $149.5799. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request. F4 Sale prices for the transactions reported range from $147.57 to $148.5699. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request. F5 Sale prices for the transactions reported range from $148.57 to $149.5699. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request. | SEC |
| 2026-09-01 | 2026-09-02 | O'Day Daniel Patrick | Chairman & CEO | $2,2M | S — Venta en mercado abierto (programada 10b5-1)4 notas del Formulario 4 (texto original de la SEC, en inglés)F1 The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on February 25, 2026. F2 Sale prices for the transactions reported range from $146.94 to $147.92. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request. F3 Sale prices for the transactions reported range from $147.95 to $148.93. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request. F4 Sale prices for the transactions reported range from $148.96 to $149.94. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request. | SEC |
| 2026-10-01 | 2026-10-02 | O'Day Daniel Patrick | Chairman & CEO | $2,2M | S — Venta en mercado abierto (programada 10b5-1)3 notas del Formulario 4 (texto original de la SEC, en inglés)F1 The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on February 25, 2026. F2 Sale prices for the transactions reported range from $147.21 to $148.205. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request. F3 Sale prices for the transactions reported range from $148.23 to $149.13. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request. | SEC |
| 2026-06-01 | 2026-06-02 | O'Day Daniel Patrick | Chairman & CEO | $2,0M | S — Venta en mercado abierto (programada 10b5-1)4 notas del Formulario 4 (texto original de la SEC, en inglés)F1 The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on February 25, 2026. F2 Sale prices for the transactions reported range from $130.66 to $131.64. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request. F3 Sale prices for the transactions reported range from $131.71 to $132.70. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request. F4 Sale prices for the transactions reported range from $132.71 to $133.295. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request. | SEC |
| 2026-08-03 | 2026-08-04 | O'Day Daniel Patrick | Chairman & CEO | $2,0M | S — Venta en mercado abierto (programada 10b5-1)4 notas del Formulario 4 (texto original de la SEC, en inglés)F1 The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on February 25, 2026. F2 Sale prices for the transactions reported range from $129.17 to $130.16. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request. F3 Sale prices for the transactions reported range from $130.18 to $131.17. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request. F4 Sale prices for the transactions reported range from $131.21 to $131.47. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request. | SEC |
| 2026-07-01 | 2026-07-02 | O'Day Daniel Patrick | Chairman & CEO | $1,9M | S — Venta en mercado abierto (programada 10b5-1)3 notas del Formulario 4 (texto original de la SEC, en inglés)F1 The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on February 25, 2026. F2 Sale prices for the transactions reported range from $125.59 to $126.55. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request. F3 Sale prices for the transactions reported range from $126.595 to $127.44. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request. | SEC |
| 2026-02-27 | 2026-03-02 | O'Day Daniel Patrick | Chairman & CEO | $1,4M | S — Venta en mercado abierto (programada 10b5-1)3 notas del Formulario 4 (texto original de la SEC, en inglés)F2 The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on February 28, 2025. F3 Sale prices for the transactions reported range from $143.63 to $144.59. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request. F4 Sale prices for the transactions reported range from $144.66 to $145.65. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request. | SEC |
| 2026-01-28 | 2026-01-29 | O'Day Daniel Patrick | Chairman & CEO | $1,4M | S — Venta en mercado abierto (programada 10b5-1)3 notas del Formulario 4 (texto original de la SEC, en inglés)F1 The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on February 28, 2025. F2 Sale prices for the transactions reported range from $138.99 to $139.97. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request. F3 Sale prices for the transactions reported range from $140.00 to $140.57. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request. | SEC |
| 2026-03-27 | 2026-03-30 | O'Day Daniel Patrick | Chairman & CEO | $1,4M | S — Venta en mercado abierto (programada 10b5-1)2 notas del Formulario 4 (texto original de la SEC, en inglés)F1 The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on February 28, 2025. F2 Sale prices for the transactions reported range from $136.51 to $137.22. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request. | SEC |
| 2026-04-28 | 2026-04-29 | O'Day Daniel Patrick | Chairman & CEO | $1,3M | S — Venta en mercado abierto (programada 10b5-1)3 notas del Formulario 4 (texto original de la SEC, en inglés)F1 The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on February 28, 2025. F2 Sale prices for the transactions reported range from $128.41 to $129.325. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request. F3 Sale prices for the transactions reported range from $129.42 to $130.47. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request. | SEC |
| 2025-11-28 | 2025-12-01 | O'Day Daniel Patrick | Chairman & CEO | $1,3M | S — Venta en mercado abierto (programada 10b5-1)3 notas del Formulario 4 (texto original de la SEC, en inglés)F1 The transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan adopted on February 28, 2025. F2 Sale prices for the transactions reported range from $125.41 to $126.33. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request. F3 Sale prices for the transactions reported range from $126.50 to $127.48. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request. | SEC |
| 2025-12-29 | 2025-12-30 | O'Day Daniel Patrick | Chairman & CEO | $1,2M | S — Venta en mercado abierto (programada 10b5-1)2 notas del Formulario 4 (texto original de la SEC, en inglés)F1 The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on February 28, 2025. F2 Sale prices for the transactions reported range from $124.40 to $125.16. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request. | SEC |
| 2025-10-28 | 2025-10-29 | O'Day Daniel Patrick | Chairman & CEO | $1,2M | S — Venta en mercado abierto (programada 10b5-1)3 notas del Formulario 4 (texto original de la SEC, en inglés)F1 The transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan adopted on February 28, 2025. F2 Sale prices for the transactions reported range from $119.08 to $120.06. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request. F3 Sale prices for the transactions reported range from $118.61 to $119.06. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request. | SEC |
El saldo del período: cuánto dinero entra y cuánto sale
En los Formularios 4 presentados entre el 29 ago 2025 y el 16 oct 2026 no consta ni una compra en mercado abierto de Gilead Sciences, Inc.: 51 ventas por $91,4M y cero dólares comprados.
Solo cuentan los códigos P y S, donde el directivo pone o saca su propio dinero. Que el saldo de Gilead Sciences, Inc. salga vendedor es lo habitual en el S&P 500, donde buena parte del sueldo se cobra en acciones. No es una recomendación de comprar ni de vender: es lo que se declaró.
Todas las transacciones, código por código
| Código | Qué significa | Operaciones | Importe declarado |
|---|---|---|---|
| S | Venta en mercado abierto | 51 | $91,4M |
| M | Ejercicio de opciones | 40 | $28,0M |
| F | Retención fiscal (acciones entregadas por impuestos) | 31 | $25,9M |
| A | Adjudicación o premio de acciones | 15 | $0 |
| Total | Todo lo declarado en el período | 137 | $145,3M |
42 de las 137 filas no traen un importe utilizable en el Formulario 4: cuentan como operación y suman $0. Las etiquetas son las del índice de códigos de la SEC.
Quién ha operado
En los 15 meses del histórico han declarado operaciones de Gilead Sciences, Inc. 16 personas o entidades distintas. De ellas, ninguna compró en mercado abierto y 7 vendieron. Se cuentan por su CIK, el número fijo que la SEC da a cada declarante, y no por el nombre, que cada uno escribe a su manera.
De los 7 que vendieron en mercado abierto (51 ventas en total), los tres que más vendieron suman $80,6M de los $91,4M: el 88% del dinero en tres personas.
| Declarante | Cargo | Transacciones | Comprado (nº) | Vendido (nº) | Última declarada |
|---|---|---|---|---|---|
| O'Day Daniel Patrick | Chairman & CEO | 31 | — | $54,7M (16) | 2026-10-02 |
| Mercier Johanna | Chief Comm & Corp Aff Officer | 31 | — | $19,3M (14) | 2026-10-16 |
| Telman Deborah H | EVP, Corporate Affairs & GC | 6 | — | $6,6M (1) | 2025-11-13 |
| Dickinson Andrew D | Chief Financial Officer | 27 | — | $5,4M (14) | 2026-10-16 |
| Welters Anthony | Consejero | 3 | — | $2,7M (1) | 2026-08-27 |
| Bluestone Jeffrey | Consejero | 7 | — | $2,0M (3) | 2026-08-21 |
| Kramer Kelly A. | Consejero | 4 | — | $713k (2) | 2025-12-01 |
| Berger Dietmar | Chief Medical Officer | 9 | — | — | 2026-09-11 |
Se enseñan los 8 que más dinero movieron, de 16. Los demás están en el histórico completo, que se abre con el enlace de arriba. El nombre lleva a todas sus operaciones, en cualquier empresa. «Transacciones» cuenta cualquier código; el dinero, solo mercado abierto. Cargo: el de su última declaración.
Mes a mes
Por el mes en que se operó, no en el que se presentó el formulario; los meses sin operaciones van a cero. El mes con más movimiento fue nov 2025: 0 compras y 7 ventas, por $13,0M. Ninguno de los 15 meses queda en blanco.
| Mes | Compras | Importe | Ventas | Importe |
|---|---|---|---|---|
| ago 2025 | 0 | $0 | 1 | $1,1M |
| sept 2025 | 0 | $0 | 3 | $1,7M |
| oct 2025 | 0 | $0 | 3 | $1,8M |
| nov 2025 | 0 | $0 | 7 | $13,0M |
| dic 2025 | 0 | $0 | 3 | $2,0M |
| ene 2026 | 0 | $0 | 5 | $18,4M |
| feb 2026 | 0 | $0 | 4 | $23,6M |
| mar 2026 | 0 | $0 | 3 | $2,2M |
| abr 2026 | 0 | $0 | 3 | $2,1M |
| may 2026 | 0 | $0 | 2 | $4,1M |
| jun 2026 | 0 | $0 | 3 | $2,7M |
| jul 2026 | 0 | $0 | 3 | $2,7M |
| ago 2026 | 0 | $0 | 5 | $9,6M |
| sept 2026 | 0 | $0 | 3 | $3,1M |
| oct 2026 | 0 | $0 | 3 | $3,2M |
El último mes puede ir incompleto: el Formulario 4 se presenta hasta dos días hábiles después. La tabla no dice si el patrón es bueno o malo; dice cuándo pasó.
Ficha de análisis de Gilead Sciences, Inc. (GILD) →
Otras empresas de Salud con operaciones de directivos
Están las 500 en el índice de la sección →
Qué directivos están comprando acciones de su propia empresa →
Cómo leer estos datos
20 de las 20 ventas de la tabla van marcadas como programadas (plan 10b5-1): se firman con meses de antelación y se ejecutan solas, así que no dicen lo que el directivo piensa hoy. Gilead Sciences no tiene ninguna compra en mercado abierto (código P) en el histórico, que es lo más común en el S&P 500: los directivos ya cobran en acciones. La última presentación es del 16 oct 2026, y el Formulario 4 llega hasta dos días hábiles después de operar.
20 de las 20 filas de la tabla llevan notas al pie del propio Formulario 4, plegadas en la columna del código y copiadas tal cual, en inglés; una fila sin nota es que el formulario no la trae.
Guía: Compras de directivos · todas las guías
Lo que hay detrás de estas operaciones
Los conceptos de esta página, explicados desde cero en la Academia. Gratis y sin cuenta.
- Qué dice y qué NO dice la hipótesis de eficienciaSi la compra de un directivo es pública y cualquiera puede leerla, ¿queda información dentro? Es la pregunta exacta que trae a esta página.
- Quién mueve realmente el mercado: los tipos de inversoresQuién hay al otro lado de cada orden, y qué sitio ocupan entre ellos los directivos de la propia empresa.
- Oferta, demanda y el precio: por qué sube y baja constantementeCómo acaba una noticia metida en el precio, y por qué la reacción a una venta declarada rara vez es la que uno esperaría.
Fuente: SEC EDGAR Formulario 4. Esto es una lista de hechos públicos, no asesoramiento financiero ni una recomendación de compra o venta.